Innovation in

ENGAGING GAMMA-DELTA T CELLS

to potently and precisely fight cancer

AT LAVA, WE ARE FOCUSED ON APPLYING

OUR EXPERTISE IN GAMMA-DELTA T CELL ENGAGERS

(TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune systems. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we believe we are the only company developing bispecific gamma-delta T cell engaging antibodies for the treatment of cancer.

Learn More

Our Approach
bispecific gamma-delta T cell engagers
Our Pipeline
novel gamma-delta T cell engaging platform
Our Team
LAVA’s Leadership
// LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic  » Full Release
// LAVA Therapeutics to Present Corporate Overview at 39th Annual J.P. Morgan Healthcare Conference  » Full Release
// LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs  » Full Release